Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab… EP News Bureau Oct 25, 2024 Australia’s Alzheimer’s patients await potential treatment shift as TGA reviews Lilly’s donanemab following lecanemab rejection
Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide:… EP News Bureau Aug 1, 2024 With promising Phase IIa results and a dual GLP-1/GIP receptor mechanism, VK2735 could soon compete directly with tirzepatide in…
FDA approves Eli Lilly’s alzheimer’s drug fda.gov Jul 3, 2024 The drug is targeted at adults in the mild cognitive impairment or mild dementia stage
